PDS Biotechnology is a clinical-stage biopharmaceutical company developing novel immunotherapies that train the body’s immune to recognize and kill cancerous cells in the body. The company is also developing novel vaccines to treat infectious diseases.
PDS’s proprietary Versamune® nano-platform is based on certain synthetic and positively charged (cationic) lipids that are able to facilitate intra-cellular delivery of disease related proteins and peptides (antigens) and to activate important immunologic signaling pathways that induce effective priming and proliferation of critical populations of T-cells that are able to specifically attack and kill cancerous cells. This ability to effectively generate high levels of disease-specific killer T-cells has been demonstrated in human clinical trials, with no limiting safety concerns even at the highest tested doses.
In addition to inducing tumor targeting T-cells, the Versamune platform has been demonstrated to suppress important immune-suppressive cells including myeloid derived suppressor cells (MDSC) and T regulatory cells (Tregs) that exist within the tumors, and are able to protect the tumor from T-cell attack. Together the various mechanisms including intracellular delivery, immune activation and reduction of immune suppressive cells provide strong potential for effective cancer therapies.
PDS’ on-going clinical program focuses on cancers caused by infection with the human papillomavirus, including cervical cancer, head and neck cancer, anal cancer, vaginal and vulvar cancers. Phase II human clinical programs are expected to begin in early 2018. PDS also plans to initiate clinical programs in prostate and ovarian cancers in 2018.
PDS has active collaborations with leading institutions including the National Cancer Institute, M.D. Anderson Cancer Center, and the University of Kentucky School of Medicine.